Comparison of TRUS-biopsy to Transperineal Template Mapping biopsies stratified by MRI score within the PROMIS trial
BAUS ePoster online library. Lovegrove C. Jun 24, 2019; 259548; P5-4
Dr. Catherine Lovegrove
Dr. Catherine Lovegrove
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
INTRODUCTION

PROMIS provided level 1 evidence for pre-biopsy MP-MRI as triage investigation for detection of clinically significant prostate cancer(csPCa). We aimed to further elaborate on performance characteristics of transrectal ultrasound-guided systematic(TRUS) biopsies compared to transperineal template mapping(TPM) biopsy with a 5mm sampling frame.

METHODS

Biopsy-naïve men advised to undergo prostate biopsy for elevated PSA and/or abnormal rectal examination underwent standardised MP-MRI, TPM-biopsy and TRUS-biopsy with tests conducted and reported blind to the results of the others. csPCa was primarily defined as detection of Gleason>/=4+3 or maximum cancer core length(MCCL)>/=6mm of any grade, and secondarily defined as Gleason>/=3+4 or any grade with MCCL>/=4mm. All cancer was also evaluated.

RESULTS

Over 41 months, 740 men from 11 centres were recruited and 576 underwent all three tests. Of 150 men with MRI score 1-2, 8(5.3%) had any Gleason >/=3+4 disease. In 75 men in whom TRUS-biopsy showed Gleason 3+3 of any MCCL, 61/75(81%) had Gleason3+4 and 8/75 (11%) Gleason 4+3; none of 75 (0%) had Gleason>/=4+5.

For definition1 csPCa, sensitivity remains broadly stable and low across all Likert scores (35% to 52%) (Table 1). For definition2 csPCa and any cancer, TRUS-biopsy sensitivity increased with Likert score (Table 2). NPV was variable but in all cancer thresholds showed decreasing trends with increasing Likert score (Tables 1-3).

Conclusions
TRUS-biopsy for MRI scores 1 and 2 confers 1 in 20 chance of yielding Gleason >/=3+4. Further, for any definition of csPCa, TRUS-biopsy had poor sensitivity and variably low negative predictive values across all MRI score groups.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings